After Dr. Sylke Hassel’s exclusive interview at CPHI Worldwide, Arul Ramadurai, CCO at Axplora, also spoke on camera to share his business vision. This interview takes us on a journey through Axplora’s legacy forged through the integration of Farmabios, Novasep, and Pharmazell, and how this heritage forms the bedrock of Axplora’s commercial strategy.
In essence, the three legacy brands have come together to offer both API products to generic companies and CDMO services to innovative big pharma and biotech companies and thus support the entire lifecycle of pharmaceutical products.
Arul underlines the unbreakable link between patients’ security and our sites’ audits and certifications to meet the customers’ expectations. And for him, security supply, high quality, and products on time are the basics that set Axplora apart as a Reliable Partner.
Last point but not least, Arul provides a glimpse into Axplora’s Environmental, Social, and Governance (ESG) strategy, not only expected by customers but also core to “our being”. Indeed, as a player in the pharmaceutical industry, Axplora is actively looking for more sustainable and cost-efficient solutions such as electrochemistry where the company has gained a unique experience and expertise to match the increased complexity of new APIs being developed.
Latest news
News
July 09, 2026
Axplora’s European CDMO network raises the bar with enhanced EcoVadis ratings across four manufacturing sites
Axplora’s Leverkusen site was awarded Platinum, with Le Mans receiving Gold, and Pompey and Chasse-sur-Rhône Silver in their first individual EcoVadis assessments. Recognition reinforces Axplora’s commitment to helping customers navigate increasingly complex supply chains with confidence through responsible, transparent and reliable manufacturing. 9 July, 2026 – Axplora, a global CDMO Partner for complex […]
News
June 10, 2026
Axplora consolidates UDCA manufacturing at Vizag site to strengthen integrated global supply and support future growth
Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and enables Farmabios to sharpen focus on Steroids and HPAPI leadership June 10th, 2026 – Axplora, a global leader in the manufacturing of small molecule APIs and ADCs for the pharmaceutical industry, today announced the strategic consolidation of ursodeoxycholic acid (UDCA) manufacturing at its Vizag, India site, part of the PharmaZell business unit. Production will transition fully from the […]
News
March 17, 2026
Biopharma’s Growing Emphasis on Highly Potent Drugs Drives Axplora Manufacturing Expansion
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy New […]
We enable our partners to fully realize their ambitions.
Driven by the curiosity, skills and dedication of over 2,000 employees on three continents, Axplora delivers sustainable, technologically advanced API solutions to improve lives worldwide.